↓ Skip to main content

Advances in immunotherapy for melanoma

Overview of attention for article published in BMC Medicine, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

8 tweeters
4 patents
1 Facebook page
1 Wikipedia page
1 Redditor


85 Dimensions

Readers on

143 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Advances in immunotherapy for melanoma
Published in
BMC Medicine, February 2016
DOI 10.1186/s12916-016-0571-0
Pubmed ID

Jason M. Redman, Geoffrey T. Gibney, Michael B. Atkins


In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal antibodies are capable of unleashing dormant or exhausted antitumor immunity, which has led to durable complete and partial responses in a large number of patients. Ipilimumab targets the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) receptor. Nivolumab and pembrolizumab target programmed cell death protein 1 (PD-1) receptors and have proven to be superior to ipilimumab alone. The combination of ipilimumab and nivolumab has yielded higher response rates, greater tumor shrinkage, and longer progression-free survival than either monotherapy alone. As other promising immunotherapies for melanoma proceed through clinical trials, future goals include defining the role of immune checkpoint inhibitors as adjuvant therapy, identifying optimal combination strategies, and developing reliable predictive biomarkers to guide treatment selection for individual patients.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Denmark 1 <1%
Canada 1 <1%
Unknown 139 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 20%
Student > Bachelor 21 15%
Student > Master 20 14%
Student > Ph. D. Student 19 13%
Other 11 8%
Other 20 14%
Unknown 24 17%
Readers by discipline Count As %
Medicine and Dentistry 37 26%
Agricultural and Biological Sciences 24 17%
Biochemistry, Genetics and Molecular Biology 24 17%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Immunology and Microbiology 5 3%
Other 19 13%
Unknown 28 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2019.
All research outputs
of 17,358,590 outputs
Outputs from BMC Medicine
of 2,703 outputs
Outputs of similar age
of 350,305 outputs
Outputs of similar age from BMC Medicine
of 1 outputs
Altmetric has tracked 17,358,590 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,703 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,305 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them